Various lines of evidence suggest that pancreatic adenocarcinoma can also induce anti-tumoral T-cell responses [7–9], thus “off-the-shelf” peptide vaccines (KRAS, Gastrin G17DT, HSP-CC-96, WT1, VEGF-R and2, hTERT, Her2/neu, KIF20A [10]), recombinant vaccines (MUC-1- and CEA-expressing poxviruses with GM-CSF), live attenuated Listeria mesothelin-expressing vaccines, irradiated whole allogenic tumor and Listeria [11], as well as inactivated whole tumor cell vaccines (Algenpantucel-L, allogeneic GM-CSF) have been evaluated for therapy in this type of cancer [12–14]. The gene discussed is CSF2; the disease is pancreatic adenocarcinoma.